Buprenorphine depot - Biotie Therapies

Drug Profile

Buprenorphine depot - Biotie Therapies

Alternative Names: Buprel

Latest Information Update: 20 Jul 2010

Price : $50

At a glance

  • Originator DrugAbuse Sciences
  • Developer Biotie Therapies Corp.
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Opioid abuse

Most Recent Events

  • 20 Jul 2010 Discontinued - Preclinical for Opioid abuse in European Union (IM)
  • 19 Jan 2007 elbion NV acquires buprenorphine depot from DrugAbuse Sciences
  • 31 Oct 2006 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top